Education
About Us
Working with TipRanks
Follow Us
Inventiva SA (FR:IVA)
:IVA
Earnings Data
Report Date
Sep 25, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.67Last Year’s EPS
-0.81Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 26, 2025
|% Change Since: 16.36%
|Next Earnings Date:Sep 25, 2025
Earnings Call Sentiment|Positive
The earnings call presented a largely positive outlook with significant progress in clinical trials, financial performance, and strategic global partnerships. However, challenges included workforce reductions and a significant increase in net loss. The highlights of strategic advancements and robust cash position outweigh the lowlights.Company Guidance
During the conference call, Inventiva provided guidance on several key metrics and strategic initiatives for the fiscal year 2024. The company reported a cash position of €96.6 million at the end of 2024, compared to €36 million at the end of 2023, primarily due to successful financing operations totaling approximately $184 million. Inventiva anticipates completing the randomization of its Phase 3 NATiV3 trial for lanifibranor by the first half of 2025, with topline results expected in the second half of 2026. The company aims to utilize its strengthened financial position to prepare for regulatory filings and potential commercialization, having already reinforced its board and development team. Despite a net loss of €184.2 million in 2024, Inventiva remains focused on advancing lanifibranor, benefiting from positive trial data and strategic partnerships in Asia, with a cash runway extending to September 2025, or potentially to September 2026 with additional financing.Progress in Clinical Development of lanifibranor
Completed screening for Phase 3 NATiV3 trial with positive recommendations from data monitoring committees, indicating no modifications are necessary. The trial is on track for completion of recruitment in H1 2025 and topline results expected in H2 2026.
Positive Financial Performance
Inventiva raised $184 million in 2024 through dilutive and non-dilutive financing operations, significantly increasing cash position to €96.6 million from €36 million in 2023.
Strategic Partnerships and Global Expansion
Launched clinical development of lanifibranor in Japan with partner Hepalys and secured licensing agreements in South Korea and China, positioning lanifibranor as a leading oral drug in MASH for these regions.
Strong Governance and Leadership Team
Reinforced Board of Directors with experienced members from the biotech industry, including Andre Turenne and Mark Pruzanski, to drive commercialization and strategic growth.
Strengthened Clinical Data Set
Published positive results from LEGEND trial showing significant reduction in HBA1C and improvement in insulin sensitivity with lanifibranor, particularly when combined with empagliflozin.
---
FR:IVA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
FR:IVA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 26, 2025 | €2.75 | €2.75 | 0.00% |
| Sep 25, 2024 | €1.88 | €1.60 | -15.11% |
| Mar 27, 2024 | €3.35 | €3.32 | -0.90% |
| Sep 28, 2023 | €3.88 | €4.11 | +5.80% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Inventiva SA (FR:IVA) report earnings?
Inventiva SA (FR:IVA) is schdueled to report earning on Sep 25, 2025, TBA Not Confirmed.
What is Inventiva SA (FR:IVA) earnings time?
Inventiva SA (FR:IVA) earnings time is at Sep 25, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Inventiva SA stock?
The P/E ratio of Inventiva is N/A.
What is FR:IVA EPS forecast?
FR:IVA EPS forecast for the fiscal quarter 2025 (Q2) is -0.67.
---